Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Chem Rec ; 24(5): e202400005, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38587150

RESUMO

α-Haloenals, especially, α-bromoenals considered as one of the important building blocks in organic synthesis. They can participate in various (3+2)-, (3+3)-, (3+4)-, and (2+4)-annulation reactions with other organic molecules in the presence of an NHC catalyst to produce enantioenriched carbo-, and heterocyclic compounds. Herein, we have described NHC-catalyzed enantioselective transformations of α-bromoenals in the synthesis of various heterocycles, and carbocycles, as well as acyclic organic compounds.

2.
Arch Pharm (Weinheim) ; 357(7): e2300517, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38593290

RESUMO

This study describes the design, synthesis, and evaluation of a novel series of phenylthiosemicarbazide-phenoxy-1,2,3-triazole-N-phenylacetamide derivatives (7a-l) as dual inhibitors of α-glucosidase and protein tyrosine phosphatase 1-B (PTB-1B). The latter enzymes are two important targets in the treatment of type 2 diabetes. The in vitro obtained data demonstrated that all title compounds 7a-l were more potent than the standard inhibitor acarbose against α-glucosidase while only four derivatives (7a, 7g, 7h, and 7h) were more potent than the standard inhibitor suramin against PTP-1B. Furthermore, these data showed that the most potent α-glucosidase inhibitor was compound 7i, with sixfold higher inhibitory activity than acarbose, and the most potent PTP-1B inhibitor was compound 7a with 3.5-fold higher inhibitory activity than suramin. Kinetic studies of compounds 7i and 7a revealed that they inhibited their target enzymes in a competitive mode. The docking study demonstrated that compounds 7i and 7a well occupied the active site pockets of α-glucosidase and PTP-1B, respectively. In silico pharmacokinetic and toxicity assays of the most potent compounds were performed, and the obtained results were compared with those of the standard inhibitors.


Assuntos
Diabetes Mellitus Tipo 2 , Inibidores de Glicosídeo Hidrolases , Hipoglicemiantes , Simulação de Acoplamento Molecular , Proteína Tirosina Fosfatase não Receptora Tipo 1 , alfa-Glucosidases , Diabetes Mellitus Tipo 2/tratamento farmacológico , Inibidores de Glicosídeo Hidrolases/farmacologia , Inibidores de Glicosídeo Hidrolases/síntese química , Inibidores de Glicosídeo Hidrolases/química , Proteína Tirosina Fosfatase não Receptora Tipo 1/antagonistas & inibidores , Proteína Tirosina Fosfatase não Receptora Tipo 1/metabolismo , Relação Estrutura-Atividade , Humanos , alfa-Glucosidases/metabolismo , Hipoglicemiantes/farmacologia , Hipoglicemiantes/síntese química , Hipoglicemiantes/química , Estrutura Molecular , Triazóis/farmacologia , Triazóis/química , Triazóis/síntese química , Relação Dose-Resposta a Droga , Semicarbazidas/farmacologia , Semicarbazidas/química , Semicarbazidas/síntese química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA